Rhumbline Advisers Buys New Holdings in CRISPR Therapeutics AG $CRSP

Rhumbline Advisers acquired 123,893 shares of CRISPR Therapeutics AG, valued at approximately $6,026,000, in the second quarter. This purchase represents 0.14% ownership of the company. Other hedge funds have also adjusted their positions in CRISPR Therapeutics. The stock is trading at $55.99 with a market cap of $5.34 billion. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and a price target of $67.42.

Rhumbline Advisers purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 123,893 shares of the company's stock, valued at approximately $6,026,000. Rhumbline Advisers owned 0.14% of CRISPR Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Get CRISPR Therapeutics alerts:

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

A number of other hedge funds also recently made changes to their positions in the business. Avantax Advisory Services Inc. boosted its stake in shares of CRISPR Therapeutics by 55.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 10,651 shares of the company's stock worth $362,000 after acquiring an additional 3,815 shares during the period. Cetera Investment Advisers lifted its holdings in CRISPR Therapeutics by 94.1% during the 1st quarter. Cetera Investment Advisers now owns 57,919 shares of the company's stock valued at $1,971,000 after purchasing an additional 28,084 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in CRISPR Therapeutics by 3.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,093 shares of the company's stock worth $786,000 after purchasing an additional 876 shares during the period. XTX Topco Ltd increased its holdings in shares of CRISPR Therapeutics by 22.3% in the first quarter. XTX Topco Ltd now owns 10,907 shares of the company's stock valued at $371,000 after purchasing an additional 1,988 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of CRISPR Therapeutics by 153.3% in the first quarter. US Bancorp DE now owns 3,063 shares of the company's stock valued at $104,000 after purchasing an additional 1,854 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Up 8.5%

NASDAQ CRSP opened at $55.99 on Thursday. The company has a market cap of $5.34 billion, a price-to-earnings ratio of -10.02 and a beta of 1.74. The company has a 50 day moving average of $61.43 and a 200-day moving average of $55.08. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48.

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $82.00 to $74.00 and set a "buy" rating for the company in a report on Wednesday, November 26th. Needham & Company LLC reduced their price objective on CRISPR Therapeutics from $81.00 to $80.00 and set a "buy" rating for the company in a report on Monday, November 10th. Zacks Research raised CRISPR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th. Barclays lifted their price target on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Wedbush decreased their price objective on CRISPR Therapeutics from $13.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, November 5th. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $67.42.

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

View Our Latest Research Report on CRSP

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares in the company, valued at $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm's stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 56,213 shares of company stock worth $3,810,458 in the last 90 days. 4.30% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Should You Invest $1,000 in CRISPR Therapeutics Right Now?

Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here